PharmaFin — Financials Database

Trend

Y-axis

R&D basis: US (10-K) R&D includes acquired IPR&D from M&A — hover a point for the acquired portion. Foreign (20-F/IFRS) filers don’t report it the same way, so their R&D may understate M&A years.

Data table

click a column to sort

No rows match your filters.

R&D as % of revenue

R&D ÷ revenue by fiscal year · click a column to sort

Y-axis

No companies have both revenue and R&D in the selected range.

SG&A as % of revenue

SG&A ÷ revenue by fiscal year · click a column to sort

Y-axis

No companies have both revenue and SG&A in the selected range.

Preview data is normalized from an earlier scrape; foreign filers use approximate annual-average FX. For production figures, load the live scraper CSV. Verify against source filings before commercial use.

Data sources & methodology

Figures are pulled primarily from each issuer's structured XBRL data (SEC EDGAR “company facts” API) and their 10-K / 20-F annual reports, normalised to USD millions (foreign currencies converted at annual-average FX). A small number of values use a curated overrides table where issuers tag line items with non-standard XBRL concepts. Use the links below to open each company's annual filings on SEC EDGAR. R&D comparability: separately-stated “Acquired in-process R&D” is folded into R&D for 10-K filers that report it on its own line (curated, since the XBRL tag varies by filer); 20-F filers do not disclose it separately, so cross-filer R&D is approximate in M&A-heavy years.

Clinical trials activity

Y-axis

Basis: “Ongoing” is a point-in-time snapshot per fiscal year (KPI shows the latest selected year); started, completed/terminated and patient counts are annual flows summed across the selected range. The phase toggle sums the selected phase(s) per company.

Trials table

click a column to sort

No trials match your filters.

Baked from clinical_trials_annual_summary.xlsx. Load a scraper-exported CSV with the same column headers (Year, Company, “Phase 1 - Trials Started”…) to replace it.

R&D efficiency — financials × clinical trials

per company over the selected year range · click a column to sort R&D→revenue lag

No companies have both financial and trial data in the selected range.

Definitions: ΣR&D = total R&D spend over the range (USD $M; used for cost/patient). Conversion (lagged) = revenue growth over the payoff window ÷ R&D spent in the lag-shifted spend window. Example at a 5-yr lag on FY2016–2025: (rev 2025 − rev 2020) ÷ R&D 2016–2020 — drugs take years to reach market, so only R&D old enough to have paid off is credited, and recent spend that can't have produced revenue yet no longer drags the ratio down. Lag 0 reproduces the naive same-window metric. Still a ranking proxy, not a pass/fail at 1.0. Cost/patient = ΣR&D ÷ total patients enrolled (all phases). Patients/trial = total patients ÷ trials started. Caveats: the true lag varies by modality and company (rare-disease programs run faster than broad outcomes trials) — use the lag control to test sensitivity; the R&D line includes acquired-IPR&D charges (10-K filers) that inflate cost/patient without trial activity; royalty/acquired-product revenue isn't from own trials; trials-only companies (Bayer, Roche, Daiichi Sankyo, Merck KGaA, CSL) and Royalty Pharma (no trials) are excluded.